In 2012, AbbVie's (NYSE:ABBV) Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013?

In the following slideshow, we reveal last year's three best-selling drugs. Blockbusters from powerhouses Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK) all made the list.